antifungal/obesity

FIELD OF THE INVENTION The present invention relates to compositions and therapeutic combinations for treating obesity in a subject comprising the administration of sterol and/or 5.alpha.-stanol absorption inhibitor(s) or combinations with obesity control medications. BACKGROUND OF THE

TECHNICAL FIELD The present invention relates in general to the field of biotechnology, more specifically, to use of a family of lipopeptides to treat or prevent obesity and obesity-related diseases including type 2 diabetes mellitus. BACKGROUND Obesity causes a group of serious diseases

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is directed to a method for treating the metabolic syndrome, obesity, prediabetes or metabolic conditions thereof, or Type 2 diabetes, and more particularly to a method for treating the metabolic syndrome, obesity,

The present invention relates to an agent for reducing the useable calorie content of food. The agent contains a compound that can effect the conversion of fructose to 5-keto-D-fructose. 5-keto-D-fructose cannot be metabolized by the human or animal body and is therefore significantly less caloric

BACKGROUND OF THE INVENTION The present invention relates to a series of compounds which are characterised by a 2-[2-(substituted phenyl-oxy, thio or methyl)-1-methylethyl]aminoethanol structure and which have valuable anti-diabetic and anti-obesity activities; in addition, they are capable of

BACKGROUND TO THE INVENTION The present invention relates to a series of compounds which are characterised by a 2-[2-(substituted phenyl-oxy, thio or methyl)-1-methylethyl]aminoethanol structure and which have valuable anti-diabetic and anti-obesity activities; in addition, they are capable of

FIELD OF THE INVENTION This invention relates to unacylated ghrelin fragments and analogs thereof as well as to their therapeutic uses. BACKGROUND Ghrelin is a peptide which was isolated from the stomach but is expressed also in many other tissues, including the endocrine pancreas. It was discovered

TECHNICAL FIELD The present invention relates to a glutamic acid derivative having a CaSR agonist activity or a pharmaceutically acceptable salt thereof as well as a preventive or therapeutic agent for diabetes or obesity comprising as an active ingredient the derivative or a pharmaceutically

TECHNICAL FIELD The present invention relates to an alkylamine derivative or a salt thereof, and a pharmaceutical agent comprising the same. More particularly, the present invention relates to a prophylactic or therapeutic agent for diabetes or obesity, which comprises an alkylamine derivative or a

FIELD OF THE INVENTION The invention relates to inhibitors of ghrelin O-acyltransferase, and methods of making and using them. BACKGROUND The persistent rise in the proportion of overweight individuals in Western society over the past 30 years has been associated with substantial excess morbidity

RELATED APPLICATIONS This is a .sctn.371 of International Application No. PCT/JP2009/063632, with an international filing date of Jul. 31, 2009 (WO 2010/013798 A1, published Feb. 4, 2010), which is based on Japanese Patent Application No. 2008-198047, filed Jul. 31, 2008, the subject matter of which

FIELD OF THE INVENTION The present invention discloses a set of genes which have been demonstrated to be anomalously regulated (i.e., dysregulated) in a model of combining a pathophysiological predisposition towards stroke, hypertension, diabetes and obesity. The present invention also relates to

BACKGROUND The present invention relates to a reconstitutable composition comprising at least one alginate, an aqueous diet preparation comprising said composition and the use of the aqueous diet preparation for the treatment and/or prevention of overweight for both therapeutic and non-therapeutic

BACKGROUND OF THE INVENTION Research has identified that long term use of medications for treatment of obesity in patients has resulted in many problems. The two most significant problems encountered by patients using medications to assist in weight loss, assuming the absence of irreversible side

REFERENCES Safer than Phen-Fen (copyright 1997), Written by Michael Anchors, MD Ph.D. Pulmonary Vascular Disease, Medical Clinics of North America Nov. 6. 1997, Written by Donald Heath, MD Ph.D. The "Phen-pro" Diet Drug Combination Is Not Associated with Valvular Heart Disease. Jan. 12, 1998